What is Seagen Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Seagen's interest expense for the
three
months ended in Sep. 2023 was $ 0 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $0 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Seagen's Operating Income for the
three
months ended in Sep. 2023 was $ -231 Mil. Seagen's Interest Expense for the
three
months ended in Sep. 2023 was $ 0 Mil.
GuruFocus does not calculate Seagen's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Seagen Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seagen (NAS:SGEN) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Seagen's Interest Expense for the
three
months ended in Sep. 2023 was $0 Mil. Its
Operating Income
for the
three
months ended in Sep. 2023 was $-231 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Sep. 2023 was $113 Mil.
Seagen's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as
| GuruFocus does not calculate Seagen's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Seagen Inc has enough cash to cover all of its debt. Its financial situation is stable.
Seagen (Seagen) Business Description
Traded in Other Exchanges
N/A
Address
21823 - 30th Drive South East, Bothell, WA, USA, 98021
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Executives
| David R Epstein |
director, officer: Chief Executive Officer |
INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019 |
| Vaughn B Himes |
officer: See Remarks |
C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021 |
| Charles R Romp |
officer: EVP, Commercial |
21823 30TH DRIVE SE, BOTHELL WA 98021 |
| Roger D Dansey |
officer: See Remarks |
21823 30TH DRIVE SE, BOTHELL WA 98021 |
| Jean I Liu |
officer: GC & EVP, Legal Affairs |
21823 30TH DRIVE SE, BOTHELL WA 98021 |
| Todd E Simpson |
officer: Chief Financial Officer |
|
| Daniel G Welch |
director |
4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707 |
| David W Gryska |
director |
749 N MARY AVE, SUNNYVALE CA 94085 |
| Sandra M Swain |
director |
21823 30TH DRIVE SE, BOTHELL WA 98021 |
| Ted W Love |
director |
C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
| Clay B Siegall |
director, officer: President and CEO |
21823 30TH DR SE, BOTHELL WA 98021 |
| Baker Bros. Advisors Lp |
director, 10 percent owner |
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
| Felix Baker |
director, 10 percent owner |
BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
| Julian Baker |
director, 10 percent owner |
BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
| Baker Brothers Life Sciences Lp |
director, 10 percent owner |
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Seagen (Seagen) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGEN has been successfully added to your 